Ethan Binder, MD
Hematology & Oncology · Rio Rancho, NMNPI 1598028540
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,200 of the $15,759 with a category attached, or 64.7%. ADC Therapeutics America, Inc. accounts for 72.8% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2022 at $11,478 and has fallen 93.5% since, to $750 in 2025.
Across 245 payments — averaging $64.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$11K
- Novartis$579
- Gilead$362
- Pfizer$347
- Johnson & Johnson$263
- E.r. Squibb & Sons, L.L.C.$245
- plus $2K from 34 others
What the payments were for
- Consulting fees$10,20065%
- Travel & lodging$1,1287%
- Food & beverage$4,21227%
- Education$2191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 7 | $11,477 |
| Novartis | 41 | $579 |
| Gilead(2 entities) | 20 | $362 |
| Pfizer | 19 | $347 |
| Johnson & Johnson(2 entities) | 14 | $263 |
| E.r. Squibb & Sons, L.L.C. | 16 | $245 |
| Astellas Pharma US Inc | 9 | $241 |
| Seagen Inc. | 19 | $220 |
| AstraZeneca | 10 | $198 |
| AbbVie | 10 | $196 |
| Incyte Corporation | 3 | $156 |
| Genentech USA, Inc. | 7 | $115 |
| Merck | 6 | $113 |
| GSK | 6 | $103 |
| Bayer | 6 | $101 |
| Eisai Inc. | 5 | $96 |
| Bristol Myers Squibb | 4 | $87 |
| Array Biopharma Inc | 6 | $78 |
| Boehringer Ingelheim | 3 | $71 |
| Exelixis Inc. | 4 | $71 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Sanofi | 2 | $58 |
| Puma Biotechnology, Inc. | 3 | $54 |
| Geron Corporation | 2 | $48 |
| Beigene USA, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Amgen | 2 | $33 |
| Genmab U.S., Inc. | 2 | $31 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Servier Pharmaceuticals LLC | 1 | $27 |
| Tersera Therapeutics LLC | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| AVEO Pharmaceuticals, Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Springworks Therapeutics, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Beone Medicines USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MONJUVI$122
How this compares
$15,759 in reported general payments places this provider in the 85th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 102 | $1,393,201 |
| RevlimidLenalidomide | 55 | $1,008,749 |
| CalquenceAcalabrutinib Maleate | 54 | $832,496 |
| VenclextaVenetoclax | 56 | $781,149 |
| ImbruvicaIbrutinib | 33 | $512,259 |
| BrukinsaZanubrutinib | 33 | $439,431 |
| JakafiRuxolitinib Phosphate | 31 | $419,008 |
| PomalystPomalidomide | 22 | $382,218 |
| PromactaEltrombopag Olamine | 38 | $364,531 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $339,594 |
| XtandiEnzalutamide | 21 | $309,784 |
| Abiraterone Acetate | 114 | $276,439 |
| LenvimaLenvatinib Mesylate | 11 | $275,634 |
| KisqaliRibociclib Succinate | 16 | $265,212 |
| SprycelDasatinib | 22 | $225,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $198 | $1,021,20766 claims |
| Bristol Myers SquibbRevlimid | $87 | $1,008,74955 claims |
| AbbVieVenclexta, Creon | $196 | $841,68188 claims |
| NovartisPromacta, Kisqali | $579 | $629,74354 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $245 | $607,26144 claims |
| Beigene USA, Inc.Brukinsa | $41 | $439,43133 claims |
| Incyte CorporationJakafi | $156 | $419,00831 claims |
| GSKOjjaara | $103 | $339,59412 claims |
| Astellas Pharma US IncXtandi | $241 | $309,78421 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $31 | $276,439114 claims |
| Eisai Inc.Lenvima | $96 | $275,63411 claims |
| PfizerEliquis | $347 | $97,473136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Rio Rancho
- Manoj KumarRio Rancho$3K
- Usha VenkatrajRio Rancho$2K
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- Sardar ImamFarmington$24K
- George AtwehAlbuquerque$24K
- Ankit AnandFarmington$16K
- Scott HerbertAlbuquerque$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.